VBact

Company Overview

Snapshot

Founded in January 2016 by Oz Bornsetin and Dan Zemer, VBact operates with 1–10 employees. The company has completed 2 funding rounds, focusing on developing automated inline microbial imaging and quantification systems. VBact holds a patent for its technology, underscoring its commitment to innovation in industrial water monitoring.

Business overview

VBact develops automated systems for the rapid detection and quantification of viable bacteria in liquid samples. Its core technology utilizes a proprietary concentration process coupled with advanced optical imaging to identify and count microorganisms in real-time, offering actionable results significantly faster than traditional culture-based methods. The company serves industrial water treatment, pharmaceutical manufacturing, and food and beverage production lines, operating within the Industrial Technologies sector with a focus on operational optimization and process automation.

Strategic signal

VBact's continuous participation in industry events, as highlighted by its news and events page, indicates an ongoing effort to engage with the market and showcase its automated microbial imaging and quantification systems. This consistent presence suggests a strategy focused on market visibility and direct engagement with potential clients in industrial water treatment, pharmaceuticals, and food and beverage sectors, signaling a proactive approach to business development and adoption.

Company Intelligence Q&A

What is VBact's core technology?

VBact's core technology involves automated systems that use a proprietary concentration process and advanced optical imaging to rapidly detect and quantify viable bacteria in liquid samples, providing real-time results.

When was VBact founded and by whom?

VBact was founded in January 2016 by Oz Bornsetin, who serves as Co-founder & CEO, and Dan Zemer, Co-Founder & CTO.

In which industries does VBact primarily operate?

VBact primarily operates in the Industrial Technologies sector, specifically targeting industrial water treatment, pharmaceutical manufacturing, and food and beverage production lines.

What is the primary benefit of VBact's technology?

The primary benefit of VBact's technology is its ability to provide rapid, actionable results for microbial detection within minutes or hours, significantly faster than traditional culture-based methods, which enables proactive contamination management.

How many funding rounds has VBact completed?

VBact has completed 2 funding rounds, with the most recent being a debt financing round in June 2022 and a Seed round in September 2017.